RLI Corp. heads into its July 21 earnings with an unusual split: executives bought shares aggressively near lows just weeks ago, yet short sellers have spent the past month rebuilding positions at a pace that now puts bearish conviction at its highest level in the trailing 30-day window.
The insider signal is the harder one to dismiss. In late May and early June, five executives — including CEO Craig Kliethermes, COO Jennifer Klobnak, the Independent Chairman, and two directors — collectively purchased shares worth more than $1.1 million in open-market buys. Kliethermes alone bought 10,000 shares across two tranches at $52, a price roughly 16% below Tuesday's close of $62.12. The coordinated nature of those purchases, spread across multiple roles at the same price levels, is a cluster that the market tends to take seriously. The stock has since rallied 19% over the past month, validating the timing.
Short sellers read the same tape differently. Short interest has climbed 33% in 30 days, reaching 7.7% of the free float — a level that demands attention for a mid-cap insurer in a relatively quiet rate environment. The week's move alone was nearly 4%, adding around 165,000 shares to the short book. Borrow remains cheap at 0.45%, down 12% on the week, and availability is comfortable at 272% — meaning roughly 2.7 shares are available to borrow for every one already lent. That combination of rising short interest and loose borrow conditions suggests the build is demand-led conviction, not a technical squeeze or forced covering dynamic. Days to cover runs at six days on the official FINRA data, so any rapid reversal around the earnings print would create real friction for the short side.
Options lean cautiously bearish in absolute terms, though not dramatically so relative to recent history. The put/call ratio of 3.17 is above its 20-day average of 3.06 but only about half a standard deviation elevated — roughly in line with what has become a structurally put-heavy market for this name over the past two months. The 52-week range for the PCR runs from zero to nearly 9, suggesting the current reading is unremarkable as a directional signal. What is notable is that the ratio has drifted down from above 3.4 in late June, pointing to a modest reduction in demand for downside protection even as short interest has climbed.
The Street itself is split. Keefe, Bruyette & Woods raised their target to $70 this week while maintaining an Outperform — a move that matters given the analyst's familiarity with the name across multiple prior adjustments. Wells Fargo sits at Equal-Weight with a $55 target, well below the current price, while Jefferies upgraded to Hold earlier in the year at $52. The consensus mean target of $58.25 now sits below the market price at $62.12, which typically signals the Street is running to catch up with a stock that has moved faster than models assumed. The ORTEX short score has ticked up to 63, from 57.6 two weeks ago, reflecting the acceleration in short positioning. Factor scores are a mixed bag: the dividend rank reads in the 90th percentile — reinforced by a $2.00 special dividend declared in May — while EPS momentum over 30 and 90 days ranks in the bottom quintile of the universe, a reminder that the bull case rests more on capital return and niche underwriting discipline than on near-term earnings momentum.
Earnings history adds context worth holding. The last three prints produced moves of +6.4%, -7.5%, and -5.9% on the day, with five-day drifts amplifying each move in the same direction. For a stock where both insiders and short sellers have taken unusually active positions in the weeks leading up to July 21, the print's reception in the casualty reserve lines and E&S submissions data will be the deciding factor between a short squeeze and a validation of the bear thesis.
See the live data behind this article on ORTEX.
Open RLI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
